Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and absolute bioavailability study of PF-06826647 in healthy male volunteers
NL-OMON50100Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropsacitinib in psoriasis, autoimmune colitis, hidradenitis suppurativa (HS) and 1 more, sponsored by Pfizer. Primary endpoint: Total recovery of radioactivity in urine and feces. Started Nov 2020; status: active, not recruiting.
02
Drugs
ropsacitinib
03
Conditions
psoriasisautoimmune colitishidradenitis suppurativa (HS)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON50100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50100.